Verve Therapeutics Inc.
13F holders, Q1 2026 (March 31)3holders
1new positions
1sold out
$0.00avg. 13F price*
At the end of Q1 2026, 3 institutions reported holding Verve Therapeutics Inc. in their 13F filings, unchanged from Q4 2025. 1 opened new positions and 1 sold out. The largest holders were Cim Investment Management Inc. ($0), Financial Gravity Asset Management, Inc. ($0) and Murphy & Mullick Capital Management Corp ($0).
- Company
- Verve Therapeutics Inc.
- CUSIP
- 925CVR011
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 1 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 1,326 shares bought and 257 shares sold, net +1,069 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Cim Investment Management Inc. | 0.00% | Add +5.2% | 27,072 | $0 |
| Financial Gravity Asset Management, Inc. | 0.00% | New | 1 | $0 |
| Murphy & Mullick Capital Management Corp | 0.00% | No change | 43 | $0 |
"% of holder's portfolio" is VERVE THERAPEUTICS INC's weight in each manager's 13F, not the share of Verve Therapeutics Inc. the manager owns.